Sugi Predict

Sugi Predict / Compounds / SCHEMBL2857359

SCHEMBL2857359

SCHEMBL2857359

N#Cc1cccc(COc2cccc3c2CCNC3)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 2/20 0.52
▸ MRGPRX4 Q96LA9 3/20 0.49
▸ SLC6A4 P31645 2/20 0.48
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ MET P08581 1/20 0.44
▸ RXRB P28702 2/20 0.43
▸ RXRA P19793 1/20 0.43
▸ DRD2 P14416 2/20 0.43
▸ DRD3 P35462 2/20 0.43
▸ PNMT P11086 1/20 0.43
▸ CFD P00746 1/20 0.42
▸ F11 P03951 1/20 0.42
▸ CCR5 P51681 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ CD44 P16070 1/20 0.40
▸ SGMS2 Q8NHU3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3798819 0.99 HTR6 (0.51) HTR6MRGPRX4SLC6A4MAOAMAOB
SCHEMBL5016341 0.83 RXRB (0.48) HTR6MRGPRX4SLC6A4RXRBRXRA
SCHEMBL13190494 0.82 CD44 (0.49) HTR6MRGPRX4MAOBRXRBRXRA
SCHEMBL30199275 0.78 MAOB (0.58) HTR6MRGPRX4MAOAMAOBDRD2
SCHEMBL29097855 0.78 MAOB (0.58) HTR6MRGPRX4MAOAMAOBDRD2
SCHEMBL2808805 0.74 CARM1 (0.48) HTR6MRGPRX4MAOAMAOBMET
SCHEMBL3795155 0.73 AR (0.46) MRGPRX4DRD2DRD3PNMTCD44
SCHEMBL8185445 0.73 CD44 (0.51) MAOBPNMTCD44
SCHEMBL17585081 0.72 CD44 (0.47) SLC6A4MAOBPNMTCD44
SCHEMBL29098107 0.72 HDAC1 (0.48) SLC6A4RXRBRXRADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 — — US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 — — US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 — — US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 — — US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 — — US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 — — US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 — — US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 — — US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 — — US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 HTR6 387/4885MRGPRX4 16/4885SLC6A4 1214/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 HTR6 696/4885MRGPRX4 6/4885SLC6A4 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.